Last reviewed · How we verify

Placebo to Ondansetron

Helsinn Healthcare SA · Phase 3 active Small molecule

Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.

Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.

At a glance

Generic namePlacebo to Ondansetron
SponsorHelsinn Healthcare SA
Drug class5-HT3 receptor antagonist
Target5-HT3 receptor
ModalitySmall molecule
Therapeutic areaOncology, Gastroenterology, Anesthesia
PhasePhase 3

Mechanism of action

Ondansetron selectively antagonizes 5-hydroxytryptamine (serotonin) at the 5-HT3 receptor, which is located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By blocking these receptors, it prevents the transmission of emetic signals that would otherwise trigger the vomiting center, making it highly effective for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: